|
Aug 8
|
QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook
|
|
Aug 8
|
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
|
|
Aug 7
|
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
|
|
Aug 7
|
Investors in Qiagen (NYSE:QGEN) have seen returns of 21% over the past five years
|
|
Apr 24
|
QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
|
|
Apr 20
|
QIAGEN announces expansion of Supervisory Board
|